برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️Motegrity (prucalopride) Tablets Date of Approval: December 14, 2018 Company: Shire plc Treatment for: Chronic Idiopathic Constipation Motegrity (prucalopride) is a selective serotonin type 4 (5‑HT4) receptor agonist for the treatment of chronic idiopathic constipation (CIC) in adults. https://t.me/ppdprogram

➡️Tolsura (itraconazole) Capsules Date of Approval: December 11, 2018 Company: Mayne Pharma Treatment for: Blastomycosis; Histoplasmosis; Aspergillosis Tolsura (itraconazole) is an azole antifungal indicated for the treatment of certain fungal infections including blastomycosis, histoplasmosis and aspergillosis. https://t.me/ppdprogram

➡️Elepsia XR (levetiracetam) Extended-Release Tablets Date of Approval: December 20, 2018 Company: Sun Pharma Global Treatment for: Epilepsy Elepsia XR (levetiracetam) is an extended-release formulation of the antiepileptic drug levetiracetam designed to reduce pill burden in patients receiving high doses for the treatment of partial onset seizures. https://t.me/ppdprogram

➡️Dextenza (dexamethasone) Ophthalmic Insert Date of Approval: November 30, 2018 Company: Ocular Therapeutix, Inc. Treatment for: Postoperative Ocular Inflammation, Conjunctivitis, Allergic Dextenza (dexamethasone ophthalmic insert) is a corticosteroid intracanalicular insert for the treatment of post-surgical ocular inflammation and pain, and ocular itching associated with allergic conjunctivitis https://t.me/ppdprogram

➡️Aemcolo (rifamycin) Delayed-Release Tablets Date of Approval: November 16, 2018 Company: Cosmo Technologies, Ltd. Treatment for: Traveler's Diarrhea Aemcolo (rifamycin) is a broad spectrum, orally non-absorbable antibiotic for the treatment of traveler’s diarrhea caused by noninvasive strains of Escherichia coli. https://t.me/ppdprogram

➡️Yupelri (revefenacin) Inhalation Solution Date of Approval: November 9, 2018 Company: Theravance Biopharma, Inc. Treatment for: COPD Yupelri (revefenacin) is a long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD). https://t.me/ppdprogram

➡️Bryhali (halobetasol propionate) Lotion - formerly Jemdel Date of Approval: November 6, 2018 Company: Ortho Dermatologics Treatment for: Plaque Psoriasis Bryhali (halobetasol propionate) is a high-potency topical corticosteroid formulation for the treatment of plaque psoriasis in adults. https://t.me/ppdprogram

➡️Dsuvia (sufentanil) Sublingual Tablets Date of Approval: November 2, 2018 Company: AcelRx Pharmaceuticals, Inc. Treatment for: Pain Dsuvia (sufentanil) is a synthetic opioid analgesic formulation for the management of acute pain that is severe enough to require an opioid analgesic, and for which alternative treatments are inadequate. https://t.me/ppdprogram

➡️Bijuva (estradiol and progesterone) Capsules - formerly TX-001HR Date of Approval: October 28, 2018 Company: TherapeuticsMD, Inc. Treatment for: Menopausal Vasomotor Symptoms Bijuva (estradiol and progesterone) is a bio-identical hormone combination for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) due to menopause. https://t.me/ppdprogram

➡️Xofluza (baloxavir marboxil) Tablets and Granules for Oral Suspension Date of Approval: October 24, 2018 Company: Genentech, Inc. Treatment for: Influenza Xofluza (baloxavir marboxil) is a polymerase acidic (PA) endonuclease inhibitor for the treatment of influenza, and for the post-exposure prophylaxis of influenza in people 12 years of age and older. https://t.me/ppdprogram

➡️Talzenna (talazoparib) Capsules Date of Approval: October 16, 2018 Company: Pfizer Inc. Treatment for: Breast Cancer Talzenna (talazoparib) is an oral poly ADP ribose polymerase (PARP) inhibitor indicated for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. https://t.me/ppdprogram

➡️Yutiq (fluocinolone acetonide) Intravitreal Implant Date of Approval: October 12, 2018 Company: EyePoint Pharmaceuticals, Inc. Treatment for: Non-Infectious Posterior Segment Uveitis Yutiq (fluocinolone acetonide) is a corticosteroid intravitreal implant indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. https://t.me/ppdprogram

➡️Nuzyra (omadacycline) Tablets and Lyophilized Powder for Injection Date of Approval: October 2, 2018 Company: Paratek Pharmaceuticals, Inc. Treatment for: Skin and Structure Infection, Pneumonia Nuzyra (omadacycline) is an aminomethylcycline tetracycline antibiotic for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) https://t.me/ppdprogram

➡️Seysara (sarecycline) Tablets Date of Approval: October 1, 2018 Company: Almirall, S.A. Treatment for: Acne Seysara (sarecycline) is an oral, narrow spectrum tetracycline-derived antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. https://t.me/ppdprogram

➡️Arikayce (amikacin liposome) Inhalation Suspension Date of Approval: September 28, 2018 Company: Insmed, Inc. Treatment for: Mycobacterium Avium Complex (MAC) Lung Disease Arikayce (amikacin liposome inhalation suspension) is an aminoglycoside antibacterial indicated for the treatment of Mycobacterium avium complex (MAC) lung disease in adults who have limited or no alternative treatment options. https://t.me/ppdprogram

➡️Lumoxiti (moxetumomab pasudotox-tdfk) Injection Date of Approval: September 13, 2018 Company: AstraZeneca and MedImmune Treatment for: Hairy Cell Leukemia Lumoxiti (moxetumomab pasudotox-tdfk) is an anti-CD22 recombinant immunotoxin for the treatment of adult patients with hairy cell leukemia. https://t.me/ppdprogram

➡️Jivi (antihemophilic factor [recombinant] PEGylated-aucl) Injection Date of Approval: August 30, 2018 Company: Bayer HealthCare LLC Treatment for: Hemophilia A Jivi (antihemophilic factor (recombinant), PEGylated-aucl) is a recombinant DNA-derived, Factor VIII concentrate indicated to treat and control bleeding in patients with hemophilia A. https://t.me/ppdprogram

➡️Xerava (eravacycline) Injection Date of Approval: August 27, 2018 Company: Tetraphase Pharmaceuticals, Inc. Treatment for: Complicated Intra-Abdominal Infections Xerava (eravacycline) is a fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections. https://t.me/ppdprogram

➡️Altreno (tretinoin) Lotion Date of Approval: August 23, 2018 Company: Ortho Dermatologics Treatment for: Acne Altreno (tretinoin) is a topical retinoid for the treatment of acne. https://t.me/ppdprogram

➡️Inveltys (loteprednol etabonate) Ophthalmic Suspension Date of Approval: August 22, 2018 Company: Kala Pharmaceuticals, Inc. Treatment for: Postoperative Ocular Inflammation Inveltys (loteprednol etabonate) is a nanoparticle ocular corticosteroid formulation for the treatment of post-operative ocular inflammation and pain. https://t.me/ppdprogram